Immuneering Corp (IMRX)

03:55 AM

Evaluating Immuneering Corporation with trendline analysisQuarterly Market Review & Real-Time Stock Price Movement Reports - newser.com

03:55 AM

07:11 AM

Immuneering Corporation stock outlook for YEARMarket Activity Summary & Accurate Entry/Exit Alerts - newser.com

07:11 AM

Oct 13, 2025

Immuneering’s Cancer Drug Bets Deliver A Market-Beating Year - Finimize

Oct 13, 2025

Oct 13, 2025

How Immuneering Corporation stock valuations compare to rivalsJuly 2025 Action & Daily Profit Focused Stock Screening - newser.com

Oct 13, 2025

Oct 13, 2025

Is Immuneering Corporation stock ready for a breakoutJuly 2025 Action & AI Enhanced Trading Signals - newser.com

Oct 13, 2025

Oct 13, 2025

Will Immuneering Corporation stock outperform value stocksJuly 2025 Rallies & Stock Timing and Entry Methods - newser.com

Oct 13, 2025

Oct 12, 2025

Forecasting Immuneering Corporation price range with options dataJuly 2025 Fed Impact & Community Consensus Picks - newser.com

Oct 12, 2025

Oct 12, 2025

Key metrics from Immuneering Corporation’s quarterly data2025 Market WrapUp & Low Drawdown Investment Ideas - newser.com

Oct 12, 2025

Oct 10, 2025

Is it too late to sell Immuneering CorporationJuly 2025 Market Mood & Safe Swing Trade Setups - newser.com

Oct 10, 2025

Oct 10, 2025

Why Immuneering Corporation stock is in analyst buy zoneJuly 2025 Retail & Risk Adjusted Buy/Sell Alerts - newser.com

Oct 10, 2025

Oct 09, 2025

Can Immuneering Corporation stock sustain market leadershipLong Setup & Community Trade Idea Sharing - newser.com

Oct 09, 2025

Oct 09, 2025

Weiss Ratings Reiterates Sell (E+) Rating for Immuneering (NASDAQ:IMRX) - MarketBeat

Oct 09, 2025

Oct 07, 2025

Insider Stock Purchases: October 07, 2025 - Quiver Quantitative

Oct 07, 2025

Oct 07, 2025

Insider Buying: Immuneering (NASDAQ:IMRX) Director Purchases 7,500 Shares of Stock - MarketBeat

Oct 07, 2025

Oct 05, 2025

Will Immuneering Corporation stock outperform Nasdaq indexJuly 2025 Setups & Verified Momentum Stock Watchlist - newser.com

Oct 05, 2025

Oct 03, 2025

Analyzing recovery setups for Immuneering Corporation investorsMarket Activity Summary & Consistent Profit Focused Trading Strategies - newser.com

Oct 03, 2025

Oct 03, 2025

What to expect from Immuneering Corporation in the next 30 daysEarnings Performance Report & Free Community Supported Trade Ideas - newser.com

Oct 03, 2025

Oct 02, 2025

Will Immuneering Corporation stock benefit from commodity prices2025 Retail Activity & Weekly High Return Stock Opportunities - newser.com

Oct 02, 2025

Oct 02, 2025

Two new option listings and three option delistings on October 2nd - TipRanks

Oct 02, 2025

Oct 02, 2025

Immuneering Corporation (NASDAQ:IMRX) Receives $17.75 Consensus PT from Analysts - Defense World

Oct 02, 2025

Oct 01, 2025

Insider Stock Purchases: October 01, 2025 - Quiver Quantitative

Oct 01, 2025

Oct 01, 2025

Feinberg Peter buys Immuneering Corp (IMRX) shares for $52,730 - Investing.com India

Oct 01, 2025

Sep 30, 2025

Positive Trial Data Supports 43% Upside for Immuneering Corporation (IMRX) - Insider Monkey

Sep 30, 2025

Sep 30, 2025

Peter Feinberg Acquires 5,000 Shares of Immuneering (NASDAQ:IMRX) Stock - MarketBeat

Sep 30, 2025

Sep 30, 2025

Will Product Innovation Drive Rajasthan Gases Limited Stock in YEARInstitutional Buying Trends & Create Your Free Watchlist Instantly - earlytimes.in

Sep 30, 2025

Sep 29, 2025

11 Best Fast Money Stocks to Buy Now - Insider Monkey

Sep 29, 2025

Sep 29, 2025

Identifying reversal signals in Immuneering Corporation2025 Analyst Calls & Risk Managed Investment Signals - newser.com

Sep 29, 2025

Sep 29, 2025

Immuneering Corporation (NASDAQ:IMRX) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat

Sep 29, 2025

Sep 27, 2025

Immuneering (NASDAQ:IMRX) Price Target Raised to $20.00 at Chardan Capital - Defense World

Sep 27, 2025

Sep 27, 2025

Immuneering Corporation's (NASDAQ:IMRX) last week's 13% decline must have disappointed individual investors who have a significant stake - Sahm

Sep 27, 2025

Sep 26, 2025

Immuneering to host call on pancreatic cancer treatment data By Investing.com - Investing.com Nigeria

Sep 26, 2025

Sep 26, 2025

Immuneering To Discuss Recently Announced Overall Survival Data From Phase 2A Clinical Trial Of Atebimetinib + Mgnp In First-Line Pancreatic Cancer Patients On September 29 - TradingView

Sep 26, 2025

Sep 26, 2025

MBX, uniQure among biotechs raising nine-figure sums: Public Equity Report - biocentury.com

Sep 26, 2025

Sep 26, 2025

Immuneering to host call on pancreatic cancer treatment data - Investing.com

Sep 26, 2025

Sep 26, 2025

Immuneering to Discuss Recently Announced Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on Monday, September 29, 2025 - The Manila Times

Sep 26, 2025

Sep 26, 2025

First-Line Pancreatic Cancer Trial Update: Immuneering to Present Survival Data for Atebimetinib + mGnP - Stock Titan

Sep 26, 2025

Sep 26, 2025

Immuneering (NASDAQ:IMRX) Price Target Raised to $30.00 at Oppenheimer - Defense World

Sep 26, 2025

Sep 25, 2025

To vanquish pancreatic at last? Immuneering scores in phase II - BioWorld MedTech

Sep 25, 2025

Sep 25, 2025

Immuneering Stock Rises 21.7% on Supply Agreement With LLY - MSN

Sep 25, 2025